Get the Stockscreener App
3.42
5.26%
-0.19
Insight Molecular Diagnostics Inc stock is traded at $3.42, with a volume of 550.86K.
It is down -5.26% in the last 24 hours and down -30.35% over the past month.
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
See More
Previous Close:
$3.61
Open:
$3.64
24h Volume:
550.86K
Relative Volume:
3.50
Market Cap:
$110.01M
Revenue:
$4.06M
Net Income/Loss:
$-50.22M
P/E Ratio:
-2.1131
EPS:
-1.6185
Net Cash Flow:
$-25.37M
1W Performance:
+13.25%
1M Performance:
-30.35%
6M Performance:
-20.47%
1Y Performance:
+0.00%
1-Day Range:
$3.2405
$3.85
1-Week Range:
$2.645
$4.071
52-Week Range:
$2.33
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Name
Insight Molecular Diagnostics Inc
Sector
Industry
Phone
949-409-7600
Address
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
3.42 | 116.13M | 4.06M | -50.22M | -25.37M | -1.6185 |
TMO
Thermo Fisher Scientific Inc
|
531.67 | 195.93B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
198.14 | 140.56B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
580.76 | 46.39B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
119.77 | 34.02B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
326.20 | 32.49B | 3.17B | 642.63M | 516.49M | 10.77 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Initiated | Lake Street | Buy |
| May-24-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-14-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Mar-17-21 | Resumed | Needham | Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-30-20 | Initiated | BTIG Research | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-30-20 | Reiterated | The Benchmark Company | Speculative Buy |
| Jul-01-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-30-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-02-20 | Initiated | Needham | Buy |
| Feb-13-19 | Initiated | Piper Jaffray | Overweight |
| Jan-29-19 | Upgrade | Janney | Neutral → Buy |
| Dec-19-18 | Resumed | Lake Street | Buy |
View All
Insight Molecular Diagnostics Inc Stock (IMDX) Latest News
IMDX: GraftAssure aims to transform transplant diagnostics with decentralized, high-margin testing - TradingView — Track All Markets
Real-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure Assay - marketscreener.com
12 Health Care Stocks Moving In Tuesday's Intraday SessionAdagio Medical Holdings (NASDAQ:ADGM), Allog - Benzinga
Kidney transplant test data heads to 3 global medical meetings - Stock Titan
Why The Insight Molecular Diagnostics (IMDX) Story Is Shifting After Cash Raise And FDA Catalyst - Yahoo Finance
IMDX Options Volatility — NASDAQ:IMDX - TradingView — Track All Markets
IMDX Options Chain — NASDAQ:IMDX - TradingView — Track All Markets
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Capital expenditures of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX - TradingView — Track All Markets
IMDX Technical Analysis & Stock Price Forecast - Intellectia AI
Insight Molecular Diagnostics Inc. Stock Forecast Summary - Meyka
Stock List: Research Stocks from Around the World - GuruFocus
BTIG reiterates Neutral rating on Insight Molecular stock By Investing.com - Investing.com Canada
BTIG reiterates Neutral rating on Insight Molecular stock - Investing.com
Insight Molecular (IMDX) Soars 22.36% During Intraday Rally — What’s Driving the Market Turbulence? - Bitget
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
IMDX CFO’s RSUs Vest as Company Withholds Shares for Taxes - Stock Titan
IMDX (IMDX) VP Yang sees RSUs vest while shares withheld for taxes - Stock Titan
CEO at Insight Molecular (IMDX) vests 47,170 RSUs with no share sale - Stock Titan
Insight Molecular Diagnostics Inc (OCX) Stock Price Quote Today & Current Price Chart - Capital.com
Trade Insight Molecular Diagnostics IncOCX CFD - Capital.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And FDA Catalyst - Yahoo! Finance Canada
Insight Molecular Diagnostics Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Needham reiterates Buy on Insight Molecular stock, $9 target By Investing.com - Investing.com India
Insight Molecular Diagnostics Inc. Q4 2025 earnings preview - MSN
Needham reiterates Buy on Insight Molecular stock, $9 target - Investing.com
Insight Molecular Diagnostics outlines $2B annual market opportunity and signals rapid commercialization push for GraftAssureDx - MSN
Earnings call transcript: Insight Molecular Diagnostics Q4 2025 reveals strategic milestones - Investing.com India
Insight Molecular Diagnostics Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
Insight Molecular Diagnostics (NASDAQ:IMDX) Soars on 285% Revenue Beat and Key FDA Submission - ChartMill
Insight Molecular Diagnostics: Q4 Earnings Snapshot - crossville-chronicle.com
IMDX: Revenue doubled and net loss narrowed as focus shifted to transplant diagnostics and kit commercialization - TradingView
IMDX: FDA submission of GraftAssureDx and strong clinical data set stage for 2026 commercialization - TradingView
IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results - The Manila Times
Insight Molecular 2025 10-K: Revenue $4.06M, Net Loss $50.22M - TradingView
Insight Molecular Diagnostics posts Q4 2025 results; revenue $1.1M in quarter, $4.1M full year - TradingView
Insight Molecular Diagnostics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - MarketScreener
Insight Molecular Diagnostics (IMDX) files GraftAssureDx with FDA and reports 2025 loss - Stock Titan
IMDX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Insight Molecular Diagnostics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Molecular Diagnostics Market Is Going to BoomKey Factors Driving Unstoppable Growth - openPR.com
IMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference - marketscreener.com
iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference - The Manila Times
Oncocyte : to Begin Trading on the Nasdaq Stock Market on March 8, 2021 - marketscreener.com
iMDx CEO, CFO to join Needham conference after March 26 results - Stock Titan
HTGMQ (HTG Molecular Diagnostics) PNK at $0.0001 19 Mar 2026: top gainer insight - Meyka
Insight Molecular Diagnostics Inc Stock (IMDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.41%
1.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):